EUDA EUDA HEALTH HLDGS LTD

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Nasdaq on January 9, 2024 indicating that the Company had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days (the “MVLS Requirement”) as required by the Nasdaq Listing Rule 5550(b)(2).

On January 16, 2024, the Company received a written notice from Nasdaq stating that the Company’s Market Value of Listed Securities has been $35 million or greater for ten consecutive business days from January 2 to January 16, 2024, and therefore the Company has regained compliance with the MVLS requirement for continued listing on the Nasdaq Capital Market.

For investor and media inquiries, please contact:

Dr. Kelvin Chen

Chief Executive Officer

EUDA Health Holdings Limited



EN
16/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EUDA HEALTH HLDGS LTD

 PRESS RELEASE

EUDA Health Announces Second Amendment to Streeterville Warrant Agreem...

EUDA Health Announces Second Amendment to Streeterville Warrant Agreement SINGAPORE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has entered into a second amendment to its previously disclosed warrant agreement with Streeterville Capital, LLC. Summary of Second Warrant Amendment Terms Under the terms of the Second Warrant Amendment dated January 13, 2026, the Company and Streeterville Capital agreed to f...

 PRESS RELEASE

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Furthe...

EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) --  EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that its wholly owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has entered into a convertible loan agreement with Shenzhen Inno Immune Co., Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutics and customised medicines for a...

 PRESS RELEASE

EUDA Health Holdings Limited Announces Amendment to Streeterville Warr...

EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered into an amendment (the “Warrant Amendment”) to its previously disclosed warrant agreement with Streeterville Capital, LLC (“Streeterville Capital”). Background on the Original Warrant Transaction As previously announced, on November 26, 2025, EUDA entered ...

 PRESS RELEASE

EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinica...

EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company,” a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital as the Company c...

 PRESS RELEASE

EUDA Health to Launch EUDA Helixé 2.0 in January 2026

EUDA Health to Launch EUDA Helixé 2.0 in January 2026 SINGAPORE, Dec. 29, 2025 (GLOBE NEWSWIRE) --  EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it will launch EUDA Helixé 2.0 in January 2026, marking the next generation upgrade of its premium youthful vitality and longevity supplement. EUDA Helixé 2.0 introduces enhancements across formulation strength, ingredient technology, delivery systems, packaging design, and global market readiness. St...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch